PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Corentec swung from a net loss in 2024 back to profitability in 2025 while expanding into the US, Japan and Latin America, and its shares currently trade below book value per share.
2025 consolidated revenue reached KRW 100.4bn with operating profit of KRW 9.1bn, lifting the operating margin back to 9.1%
Q1-Q2 2026 consolidated revenue grew, but operating profit was relatively subdued due to subsidiary performance
Building on its No.1 domestic hip-implant market position, the company is expanding hubs in the US, Mexico and Japan
The company has stated it is considering dividends and share buybacks, though concrete implementation has not been confirmed
The debt-to-equity ratio exceeded 100% from 2022-2024 before easing to 92.8% in 2025
Corentec, founded in 2000, is Korea's first dedicated artificial joint manufacturer, developing and producing hip implants, knee implants and spinal fixation devices.
The company holds design technology specialized for implant stability and mobility along with differentiated surface treatment technology, and it is known to have applied 3D printing technology to artificial joint production for the first time in the world.
Based on clinical experience with Asian body types, it focuses on customized product development and solutions.
Corentec already holds a firmly established No.1 position in the domestic hip-implant market, and on that base it has been fleshing out a mid- to long-term strategy to become a 'global leading artificial joint company.' Its overseas business runs through wholly owned US subsidiary Corentec America, complemented by the acquisition of US healthcare company Sun Healthcare International to expand its network.
In the US, sales had been concentrated in the East Coast, and the company is now adding distributors in western regions such as California to diversify geographically.
In Mexico, Corentec holds the No.2 position in the artificial joint market, and its flagship BENCOX product has completed marketing approval from Japan's Ministry of Health, Labour and Welfare, laying groundwork for the Asia-Pacific market.
In the domestic competitive landscape, it is grouped alongside orthopedic and medical device peers such as Osteonic and Hans Biomed.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩23.4B | ₩1.4B | 5.8% |
| 2025Q3 | ₩25.8B | ₩3.6B | 14.0% |
| 2025Q4 | ₩28.6B | ₩3.1B | 10.8% |
| 2026Q1 | ₩24.6B | ₩900M | 3.6% |
| 2026Q2 | ₩25.8B | ₩1.5B | 5.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩63.9B | ₩5.8B | ₩2.7B | 9.1% | 4.0% | 128.3% |
| 2023 | ₩92B | ₩7.1B | ₩5.1B | 7.7% | 7.0% | 117.3% |
| 2024 | ₩93.7B | ₩3.9B | -₩1.3B | 4.2% | −1.8% | 120.6% |
| 2025 | ₩100.4B | ₩9.1B | ₩7B | 9.1% | 8.9% | 92.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Corentec's consolidated revenue rose steadily from KRW 63.9bn in 2022 to KRW 92.0bn in 2023, KRW 93.7bn in 2024, and KRW 100.4bn in 2025.
Profitability, however, was uneven: operating profit fell from KRW 5.8bn (9.1% margin) in 2022 to KRW 7.1bn (7.7%) in 2023 and KRW 3.9bn (4.2%) in 2024, before recovering to KRW 9.1bn (9.1%) in 2025.
On the bottom line, the company posted a net loss attributable to owners of KRW 1.3bn in 2024 before swinging back to a net profit of KRW 7.0bn in 2025.
By quarter, the loss of KRW 1.0bn in Q2 2025 improved to profits of KRW 1.4bn in Q3 and KRW 3.9bn in Q4, with the profitable trend continuing into KRW 1.3bn in Q1 2026 and KRW 1.1bn in Q2 2026.
Operating profit in Q1-Q2 2026, however, came in at KRW 0.9bn and KRW 1.5bn respectively, lower than the KRW 3.6bn and KRW 3.1bn seen in Q3-Q4 2025; the company attributed this to consolidated subsidiary performance along with upfront spending tied to new product preparation in the US market and vendor diversification.
The 2024 full-year net loss occurred despite a positive operating profit, suggesting non-operating items or subsidiary-related factors weighed on the bottom line that year.
On the cash flow side, operating cash flow improved sharply to KRW 26.5bn in 2025, a marked turnaround from the negative KRW 6.6bn recorded in 2024.
The artificial joint market is expected to see structural growth driven by an aging population and rising demand for quality of life. According to the Korea IR Service's corporate research center, the global artificial joint market is projected to grow from USD 26.6bn in 2016 to USD 32.9bn in 2025.
The US is the largest market, accounting for more than 60% of the global artificial joint market; Corentec's current US market share is only around 0.2%, but the US business already makes up roughly 20% of total sales, marking it as a region with room to grow.
Japan is said to account for half of the entire Asia-Pacific artificial joint market, and Corentec has already completed marketing approval from Japan's health ministry for its flagship BENCOX product.
In the domestic market, Corentec maintains its No.1 position in hip implants, but it competes against domestic orthopedic implant makers such as Osteonic and Hans Biomed as well as large global players like Stryker and Zimmer Biomet.
The US FDA's new Quality Management System Regulation (QMSR) also poses an ongoing compliance burden for small and mid-sized Korean medical device exporters.
Corentec has stated it plans to accelerate global market expansion by developing five overseas hubs beyond the US—Mexico, Thailand, Indonesia, Malaysia and Vietnam. It has also outlined '7 core tasks' as top priorities, including upgrading its quality system and strengthening R&D agility to comply with the FDA's QMSR.
In its first-half 2026 results, the company explained that operating profit was weighed down by upfront investment tied to new product preparation in the US market and vendor diversification, while emphasizing that such investment is aimed at securing a medium- to long-term growth base.
The company said the fruits of global market expansion would be reinvested into upgrading internal systems and infrastructure while also flowing into concrete shareholder return measures such as dividends and share buybacks. However, specific dividend amounts or buyback timing have not yet been formalized.
In Japan, since marketing approval for BENCOX has already been secured, the pace at which sales materialize will be a key point to watch going forward. Continued distributor expansion into the western US and utilization of the Sun Healthcare International network are also factors worth monitoring.
Corentec shares recently trade at a discount to net asset value, that is, below book value per share. Given the shift from a net loss in 2024 to net profit in 2025, the price-to-earnings ratio calculated on the most recent four quarters has become a meaningful metric again compared to the loss-making period.
The company has not yet implemented a cash dividend, so dividend-related metrics have not been established, a point of contrast with industry peers that do pay dividends.
That said, since the company has expressed intent to expand shareholder returns through dividends and share buybacks, whether this policy becomes concrete could be a variable in future valuation discussions.
Given its small market capitalization and limited float typical of a small-cap stock, price volatility driven by supply and demand can be relatively pronounced, which is also worth factoring in.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Corentec, which posted a net loss attributable to owners of KRW 1.3bn in 2024, returned to profit with a net income of KRW 7.0bn in 2025. The operating margin also recovered from 4.2% in 2024 to 9.1% in 2025, and operating cash flow improved sharply from negative KRW 6.6bn in 2024 to positive KRW 26.5bn in 2025. This trend was underpinned by quarterly net income moving from a loss in Q2 2025 to profits in Q3 and Q4 2025.
Corentec's US market share stands at only about 0.2%, leaving room for expansion, while the US already accounts for roughly 20% of total sales. In Mexico, the company holds the No.2 market position, and it plans to develop Thailand, Indonesia, Malaysia and Vietnam as additional hubs.
Its flagship BENCOX product has already secured marketing approval from Japan's health ministry, laying the groundwork for entry into the Asia-Pacific market.
In its first-half 2026 results announcement, the company stated it would translate the fruits of global market expansion into concrete shareholder returns via dividends and share buybacks.
While specific scale and timing have not been finalized, the sharp improvement in 2025 operating cash flow can be seen as a factor supporting future return capacity.
Operating profit in Q1-Q2 2026 came in at KRW 0.9bn and KRW 1.5bn respectively, lower than the KRW 3.6bn and KRW 3.1bn recorded in Q3-Q4 2025. The company attributed this to consolidated subsidiary performance along with upfront investment costs tied to new US product preparation and vendor diversification. This illustrates that short-term margins can be pressured even as revenue grows.
Corentec posted a net loss attributable to owners of KRW 1.3bn in 2024 despite positive operating profit that year. The operating margin also fluctuated from 9.1% in 2022 to 7.7% in 2023 and 4.2% in 2024 before recovering to 9.1% only in 2025. This suggests that consolidated subsidiary performance or non-operating factors can materially affect results.
Corentec wholly owns Corentec America, its US artificial joint sales subsidiary, and there have been reports that receivables related to this subsidiary have continued to build up.
Since subsidiary performance has repeatedly been cited as a drag on consolidated operating profit, the pace of profitability improvement at overseas units is a key point to watch.
The performance and receivables management of overseas units in the US and China have a significant impact on consolidated results. Currency fluctuations can directly affect export profitability and the translation of overseas subsidiary results.
As overseas hub expansion continues, initial investment costs and the time lag before these hubs contribute to earnings also warrant attention.
Compliance with the FDA's new QMSR requires a broad overhaul of quality systems, raising the possibility of certification delays or additional costs. Even in new markets such as Japan, it can take time between obtaining marketing approval and generating actual sales. Changes in country-specific approval requirements are a variable that could affect export timelines.
Competition exists both against large global artificial joint makers and domestic peers such as Osteonic and Hans Biomed on price and technology. Given its small market capitalization and limited float, price volatility driven by supply and demand can be relatively high.
Since US market share remains low, there is also a possibility that the pace of expansion falls short of expectations.
Check whether Q3 2026 preliminary results show operating margin recovering toward Q3-Q4 2025 levels and whether one-off costs tied to US new products and vendor diversification normalize.
Monitor whether the company's stated dividend and share buyback shareholder return plans are disclosed with concrete scale and timing.
Track progress on western US distributor expansion, utilization of the Sun Healthcare International network, and changes in US market share (currently around 0.2%).
Assess the pace at which BENCOX's Japanese marketing approval translates into actual sales and progress in entering the Asia-Pacific market.
Check progress on implementing the company's '7 core tasks,' including quality system upgrades to comply with the FDA's QMSR.
Corentec successfully turned around from a net loss in 2024 to a net profit of KRW 7.0bn in 2025, with the operating margin recovering to 9.1%, showing an overall improvement in profitability.
However, operating profit in Q1-Q2 2026 came in lower than in the second half of 2025 due to upfront investment costs tied to US new product preparation and vendor diversification, along with the effect of consolidated subsidiary performance.
Building on its No.1 position in the domestic hip-implant market, the company is expanding hubs in the US, Mexico and Japan, though its US market share remains low at around 0.2%, presenting both expansion potential and uncertainty.
The company has expressed intent to expand shareholder returns through dividends and buybacks, but concrete implementation plans have not yet been formalized.
Receivables management related to overseas subsidiaries, regulatory compliance such as the FDA's QMSR, and the supply-and-demand volatility typical of small-cap stocks are variables to watch.
The upcoming Q3 preliminary results and the extent to which shareholder return policy becomes concrete are likely to be important reference points going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.